MX2023009024A - Combinaciones terapeuticas de rosuvastatina y resmetirom para el tratamiento de trastornos hepaticos o trastornos lipidicos. - Google Patents
Combinaciones terapeuticas de rosuvastatina y resmetirom para el tratamiento de trastornos hepaticos o trastornos lipidicos.Info
- Publication number
- MX2023009024A MX2023009024A MX2023009024A MX2023009024A MX2023009024A MX 2023009024 A MX2023009024 A MX 2023009024A MX 2023009024 A MX2023009024 A MX 2023009024A MX 2023009024 A MX2023009024 A MX 2023009024A MX 2023009024 A MX2023009024 A MX 2023009024A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- resmetirom
- rosuvastatin
- treatment
- therapeutic combinations
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 208000019423 liver disease Diseases 0.000 title abstract 2
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 title abstract 2
- 229940121486 resmetirom Drugs 0.000 title abstract 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 2
- 229960000672 rosuvastatin Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002648 combination therapy Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente divulgación proporciona una terapia de combinación para el tratamiento de una enfermedad o de un trastorno hepático y/o de una enfermedad o de un trastorno lipídico en un sujeto que lo necesite. De una forma específica, la terapia de combinación comprende la administración de la rosuvastatina y el resmetirom a un sujeto que lo necesite.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143977P | 2021-02-01 | 2021-02-01 | |
| PCT/US2022/014384 WO2022165227A1 (en) | 2021-02-01 | 2022-01-28 | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009024A true MX2023009024A (es) | 2023-08-09 |
Family
ID=80786904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009024A MX2023009024A (es) | 2021-02-01 | 2022-01-28 | Combinaciones terapeuticas de rosuvastatina y resmetirom para el tratamiento de trastornos hepaticos o trastornos lipidicos. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4284373A1 (es) |
| JP (1) | JP2024506848A (es) |
| KR (1) | KR20230142523A (es) |
| CN (1) | CN116847847A (es) |
| AU (1) | AU2022213405A1 (es) |
| CA (1) | CA3206392A1 (es) |
| IL (1) | IL304606A (es) |
| MX (1) | MX2023009024A (es) |
| TW (1) | TW202245775A (es) |
| WO (1) | WO2022165227A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028429D0 (en) * | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| WO2014043706A1 (en) | 2012-09-17 | 2014-03-20 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| IL266054B2 (en) * | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
-
2022
- 2022-01-28 TW TW111104089A patent/TW202245775A/zh unknown
- 2022-01-28 CA CA3206392A patent/CA3206392A1/en active Pending
- 2022-01-28 WO PCT/US2022/014384 patent/WO2022165227A1/en active Application Filing
- 2022-01-28 EP EP22704686.9A patent/EP4284373A1/en active Pending
- 2022-01-28 MX MX2023009024A patent/MX2023009024A/es unknown
- 2022-01-28 KR KR1020237028661A patent/KR20230142523A/ko unknown
- 2022-01-28 CN CN202280012886.4A patent/CN116847847A/zh active Pending
- 2022-01-28 AU AU2022213405A patent/AU2022213405A1/en active Pending
- 2022-01-28 JP JP2023546267A patent/JP2024506848A/ja active Pending
-
2023
- 2023-07-20 IL IL304606A patent/IL304606A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4284373A1 (en) | 2023-12-06 |
| KR20230142523A (ko) | 2023-10-11 |
| TW202245775A (zh) | 2022-12-01 |
| JP2024506848A (ja) | 2024-02-15 |
| IL304606A (en) | 2023-09-01 |
| CN116847847A (zh) | 2023-10-03 |
| WO2022165227A1 (en) | 2022-08-04 |
| CA3206392A1 (en) | 2022-08-04 |
| AU2022213405A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001659A (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| MX2020009773A (es) | Terapia de combinacion. | |
| WO2011146777A3 (en) | Device and method for providing a synergistic combination of phototherapy and a non-light energy modality to the brain | |
| MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| EA201491460A1 (ru) | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| WO2016051398A8 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| BR112021018591A2 (pt) | Compostos e usos dos mesmos | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| AU2021339851A8 (en) | Method of treating amyloidosis | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| CL2021000444A1 (es) | Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto. | |
| MX2023009024A (es) | Combinaciones terapeuticas de rosuvastatina y resmetirom para el tratamiento de trastornos hepaticos o trastornos lipidicos. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| ZA202201446B (en) | Methods of treating multifocal cancer | |
| AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |